Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.

Chien MH, Lee LM, Hsiao M, Wei LH, Chen CH, Lai TC, Hua KT, Chen MW, Sun CM, Kuo ML.

Evid Based Complement Alternat Med. 2013;2013:718380. doi: 10.1155/2013/718380. Epub 2013 Jun 3.

2.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

3.

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M.

Clin Cancer Res. 2008 Sep 1;14(17):5459-65. doi: 10.1158/1078-0432.CCR-07-5270.

4.

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.

J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.

PMID:
12048269
5.

Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.

Guo B, Zhang Y, Luo G, Li L, Zhang J.

Anat Rec (Hoboken). 2009 May;292(5):633-9. doi: 10.1002/ar.20893.

6.

Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis.

Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste P.

PLoS One. 2012;7(6):e39540. doi: 10.1371/journal.pone.0039540. Epub 2012 Jun 25.

7.

Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.

Zhao YC, Ni XJ, Li Y, Dai M, Yuan ZX, Zhu YY, Luo CY.

World J Surg Oncol. 2012 Aug 20;10:165. doi: 10.1186/1477-7819-10-165.

8.

Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.

Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ.

Int J Cancer. 2009 Jun 1;124(11):2709-18. doi: 10.1002/ijc.24244.

9.

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK.

Lab Invest. 2012 Aug;92(8):1115-28. doi: 10.1038/labinvest.2012.90. Epub 2012 May 28.

10.

COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer.

Liu H, Xiao J, Yang Y, Liu Y, Ma R, Li Y, Deng F, Zhang Y.

Microvasc Res. 2011 Sep;82(2):131-40. doi: 10.1016/j.mvr.2011.04.011. Epub 2011 May 4.

PMID:
21600223
11.
12.

Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.

Liu H, Yang Y, Xiao J, Yang S, Liu Y, Kang W, Li X, Zhang F.

Microvasc Res. 2014 May;93:1-8. doi: 10.1016/j.mvr.2014.02.007. Epub 2014 Mar 3.

PMID:
24603190
13.

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.

Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S.

Int J Cancer. 2007 Nov 15;121(10):2181-91.

14.

Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.

Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE.

Cancer Res. 2008 Mar 1;68(5):1581-92. doi: 10.1158/0008-5472.CAN-06-4685.

15.

Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.

Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, Young AN.

Mod Pathol. 2005 Jan;18(1):143-52.

16.

JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer.

Hao S, Yang Y, Liu Y, Yang S, Wang G, Xiao J, Liu H.

Tumour Biol. 2014 Jun;35(6):5675-87. doi: 10.1007/s13277-014-1751-1. Epub 2014 Mar 2.

PMID:
24584816
17.

Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.

Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P, Sun Y, Tritsaris K, Hansen AJ, Dissing S, Cao Y.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15894-9. Epub 2012 Sep 11.

18.

The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer.

Tsutsui S, Matsuyama A, Yamamoto M, Takeuchi H, Oshiro Y, Ishida T, Maehara Y.

Oncol Rep. 2010 Mar;23(3):621-30.

PMID:
20126999
19.

The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model.

Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y, Otsuki Y.

BMC Med. 2010 Nov 3;8:69. doi: 10.1186/1741-7015-8-69.

20.

[Intervention of rukangyin on the lymphangiogenesis in breast cancer metastasis nude spontaneous mouse model].

Li XQ, Dang XG.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1657-61. Chinese.

PMID:
22384554

Supplemental Content

Support Center